19 March 2020 
EMEA/H/C/000910/IB/0069 
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed paediatric investigation plan 
Medicinal product  
Tesavel/ sitagliptin 
See Annex A  
Pharmaceutical form(s): 
See Annex A 
Strength(s): 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
See Annex A 
Number(s) in the Community 
Register of Medicinal Products: 
Marketing authorisation holder (MAH): 
Name and address of the MAH:  Merck Sharp & Dohme B.V. 
Waarderweg 39 
2031 BN Haarlem 
NETHERLANDS 
Procedure  
Procedure number: 
EMEA/H/C/000910/IB/69 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
- the PIP for Tesavel (EMEA-000470-PIP01-08-M11) was completed as requested during WS1727 
finalised on 30 January 2020. 
-the Summary of Product Characteristics adopted by CHMP already reflected the results of studies 
conducted in compliance with this agreed paediatric investigation plan. 
 
 
 
 
 
 
 
 
 
 
